factually
Index/Topics/Diabetes and obesity treatment

Diabetes and obesity treatment

Conditions for which FDA-approved GLP-1 receptor agonists are prescribed.

Fact-Checks

3 results
Jan 17, 2026
Most Viewed

What distinguishes FDA‑approved weight‑loss drugs (like GLP‑1 agonists) from supplements marketed as ‘GLP‑1 support’?

FDA‑approved GLP‑1 receptor agonists are prescription drugs that mimic or potentiate the GLP‑1 hormone, proven in large clinical trials to lower blood sugar, reduce appetite, and produce significant, ...

Jan 27, 2026

How durable is diabetes remission after GLP‑1/GIP‑induced weight loss, and what do trials show about relapse rates?

Clinical trials and reviews show GLP‑1 and co‑agonists reliably produce large weight loss and major improvements in glycaemia that can meet criteria for diabetes remission while drugs are continued, b...

Jan 18, 2026

What protocols have been tested to prevent metabolic rebound after stopping GLP‑1 receptor agonists?

Clinical trials and systematic reviews consistently document clinically meaningful metabolic and weight rebound after stopping GLP‑1 receptor agonists, and while commentators and reviews urge “structu...